Truist Securities increased the price target for Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ: VRTX), a $121 ...

Shares of Vertex Pharmaceuticals, Inc. were in the spotlight in premarket trading Tuesday as the biotech company received ...

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.

Vertex Energy Inc., which filed for Chapter 11 bankruptcy ... Before the bankruptcy, Vertex had one of Houston’s worst-performing stock prices through the first half of 2024, decreasing by ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target hoisted by analysts at Barclays from $435.00 to $467.00 in a research report issued to clients and investors on ...

Recent acquisitions are masking Vertex's slower organic growth, which doesn't justify its current stock price. Without acquisitions, Vertex's new customer expansion in 2024 has been very limited.

This anticipated adoption, along with a projected modest market penetration, underpins the increased price target for Vertex Pharmaceuticals’ stock, contributing to Fein’s Buy rating.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target hoisted by Royal Bank of Canada from $402.00 to $407.00 in a research note issued to investors on Tuesday,Benzinga reports.